The Project Government Oversight, an public advocacy group, has asked the Food and Drug Administration to conduct another advisory panel hearing on the safety of Yaz, Yasmin, Ocella, and other drospirenone-based birth control pills in the wake of revelations that several panelists who sat on the December 2011 panel had ties to Bayer AG, the manufacturer of Yaz and Yasmin.
As previously mentioned on this blog, in December 2011 the FDA asked a panel of outside experts to evalute whether the benefits of Yaz and Yasmin are outweighed by the risk of blood clots and other related complications such as pulmonery elbolisms and deep vein thrombosis. The FDA penal voted 15-11 that the benefits of these drugs outweigh the risks.
The Project on Government Oversight has requested a reconsideration of that decision after learning of the potential conflicts of interest of three panel members. The FDA has not yet responded to the advocacy group's demand.
Dreyer Boyajian LLP represents clients who have been harmed by Yaz and Yasmin, and has extensive experience in products liability litigation. If you or someone you know has been harmed by Yaz or Yasmin, contact our office for a free consultation with a products liability attorney.